Tang Wei-min, Gou Xin, Liu Qi-xiang
Department of Urology of Kai Xian People's Hospital, Chongqing 405400, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011 Jan;27(1):97-8.
to investigate the expression of macrophage migration inhibition factor (MIF) in serum of patients with prostate cancer and its clinical significance.
the levels of serum MIF were measured by an enzyme linked immunosorbent assay (ELISA) in 36 patients with prostate cancer, 32 patients with benign prostatic hyperplasia (BPH) and 20 healthy male adults as healthy controls.
the MIF levels of patients with prostate cancer were significantly higher than those of the other two groups (p<0.05). The level of MIF was found to relate to the clinical stages and Gleason scores of prostate cancer (P<0.05).
MIF may play an important role in the oncogenesis and development of prostate cancer. The serum MIF level can be useful as a novel biomarker for the detection of prostate cancer as well as a predictor of disease progression.
探讨巨噬细胞移动抑制因子（MIF）在前列腺癌患者血清中的表达及其临床意义。
采用酶联免疫吸附测定法（ELISA）检测36例前列腺癌患者、32例良性前列腺增生（BPH）患者及20名健康男性成年人（作为健康对照）血清中MIF水平。
前列腺癌患者的MIF水平显著高于其他两组（p<0.05）。发现MIF水平与前列腺癌的临床分期和Gleason评分相关（P<0.05）。
MIF可能在前列腺癌的发生发展中起重要作用。血清MIF水平可作为检测前列腺癌的新型生物标志物以及疾病进展的预测指标。
Zotero 插件